PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Guido BOLD	10/13/2011
Andreas FLOERSHEIMER	10/19/2011
Pascal FURET	10/20/2011
Vito GUAGNANO	10/19/2011
Keiichi MASUYA	10/20/2011
Andrea VAUPEL	10/24/2011
Joseph SCHOEPFER	10/19/2011

RECEIVING PARTY DATA

Name:	Novartis Pharma AG	
Street Address:	Lichtstrasse 35	
City:	Basel	
State/Country:	SWITZERLAND	
Postal Code:	4056	

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	7795288

CORRESPONDENCE DATA

Fax Number: (617)871-3392 Phone: 617-871-4027

Email: pip_inbox.phchbs@novartis.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

via US Mail.

Correspondent Name: Nicholas Landry

Address Line 1: 220 Massachusetts Ave.

Address Line 4: Cambridge, MASSACHUSETTS 02139

ATTORNEY DOCKET NUMBER: 33484-US-PCT


REEL: 027213 FRAME: 0432

77952

PATENT

NAME OF SUBMITTER:	Nicholas J. Landry	
Total Attachments: 6		
source=33484_F_Assignment_Inv_to_PAG#page1.tif		
source=33484_F_Assignment_Inv_to_PAG#page2.tif		
source=33484_F_Assignment_Inv_to_PAG#page3.tif		
source=33484_F_Assignment_Inv_to_PAG#page4.tif		
source=33484_F_Assignment_Inv_to_PAG#page5.tif		
source=33484_F_Assignment_Inv_to_PAG#page6.tif		

PATENT REEL: 027213 FRAME: 0433



ASSIGNMENT

This Assignment Agreement is entered into by and between

Guido BOLD	citizen of Switzerland	Novartis Pharma AG
	Officerion Christiana	Werk Klybeck
		Postfach
		4002 Basel
Andreas FLOERSHEIMER	260-22-28-7	CH
Wigness LEGERSHEIMER	citizen of Germany	Novartis Pharma AG
		Werk Klybeck
		Postfach
		4002 Basel
		СН
Pascal FURET	citizen of France	Novarlis Pharma AG
		Werk Klybeck
		Postfach
		4002 Basel
		CH
Vito GUAGNANO	citizen of Italy	Novartis Pharma AG
		Werk Klybeck
		Postfach
		4002 Basel
		СН
Kelichi MASUYA	citizen of Japan	Novartis Pharma AG
		Werk Klybeck
		Postfach
		4002 Basel
		CH
Andrea VAUPEL	citizen of Germany	Novartis Pharma AG
		Werk Klybeck
		Postfach
		4002 Basel
		CH
Joseph SCHOEPFER	citizen of Switzerland	Novartis Pharma AG
		Werk Klybeck
		Postfach
		4002 Basel
		СН
	·····	

PATENT REEL: 027213 FRAME: 0434 (hereinafter "Inventor(s)"), and NOVARTIS PHARMA AG, Lichtstrasse 35,4056 Basel, Switzerland, a company organized under the laws of Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, I/We the Inventor(s) do hereby confirm and agree that, by operation of law and/or contract, and/or by the fulfillment of any and all legal requirements regarding the transfer of employee inventions in my/our country of employment, NOVARTIS PHARMA AG is the true and lawful owner of all right, title and interest in all inventions, discoveries, patents/utility models, applications, and rights described in paragraphs (1) through (8) below.

- If, however, under the laws of any country, I/We the Inventor(s) nevertheless have any ownership right, title or interest in any of the items described herein (which I/We do not believe to be the case and make no claim in or to), for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, I/We the Inventor(s) do hereby sell, assign and transfer to NOVARTIS PHARMA AG and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of our right, title and interest for all countries of the world in and to
- (1) all of our inventions and discoveries described in the provisional or non-provisional patent, utility model, or other application(s) entitled

"ORGANIC COMPOUNDS" [Patent Case 33484]

and filed in the United States Patent and Trademark Office on November 20, 2006 and accorded Application Number 10/578,826 and/or filed as a PCT International Application on November 12, 2004 and accorded International Patent Application Number PCT/EP2004/012892; and/or filed in the Great Britain on 14 November, 2003 and accorded Application Number 0326601.2;

- (2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);
- (3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees or in our/my name, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);
- (4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other

2

international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

- (5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;
- (6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;
- (7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;
- (8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by me/us if this sale, assignment and transfer had not been made.

I/We the Inventor(s) hereby authorize ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

I/We the Inventor(s) hereby covenant and agree that I/We will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment is effective as from the earliest priority date as stated above. Executed this 13 day of Octobe , 2011. BY Quido Sold L.S. Executed this 19 day of October , 2011. BY Andrew Terrheemer L.S. Andreas Floersheimer Executed this 20 day of October 20.11 BY Per und Furt L.S. Executed this 19 day of October, 2011.

BY Unto Guagnano L.S.

Executed this 20 day of October 20/1.
BY Kelichi Masuya L.S.
Executed this 24 day of October, 2011.
BY droke lle per L.S. Andrea Vaupel
Executed this
BY West belief L.S. Joseph Schoepfer
Executed this 2 day of CC+06=5, 20 M
NOVARTIS PHARMA AG
BY L.S. Sabine Zeller Authorized signatory
NOVARTIS PHARMA AG BY CHUNCH L.S.
Reto Halbeisen

Authorized signatory

ATTESTATION

I, the undersigned Civil Law Notary in Basel, Switzerland, Marius Meier, certify herewith that the signature attached heretofore is the genuine signature of **Dr. Guido Bold**, citizen of Griesenberg, Switzerland, residing in Gipf-Oberfrick, Switzerland; and of **Dr. Andreas Floersheimer**, German citizen, residing in Dornach, Switzerland; and of **Mr. Pascai Furet**, French citizen, residing in Thann, France; and of **Dr. Vito Guagnano**, Italian citizen, residing in Basel, Switzerland; and of **Mr. Kelichi Masuya**, Japanese citizen, residing in Bottmingen, Switzerland; and of **Dr. Andrea Vaupel**, German citizen, residing in Riehen, Switzerland; and of **Mr. Joseph Schoepfer**, citizen of Escholzmatt, Switzerland, residing in Riehen, Switzerland.

If urther certify that the signatures attached heretofore are the genuine signatures of Missabine Zeller, citizen of Ormalingen, Switzerland, residing in Gelterkinden, Switzerland; and of Mr. Reto Halbelsen, citizen of Wahlen/BL, Switzerland, residing in Laufel Switzerland; both acting for Novartis Pharma AG, in Basel, Switzerland, both as proxy liders, both with joint signature.

The authoriticity of the signatures was established by means of comparison.

BASEL, Swigerland, this 31th (thirty-first) day of October 2011 (two thousand and eleven)

Leg.Prot.Nr. 1385/201

M. Meier Notar

PATENT REEL: 027213 FRAME: 0439

RECORDED: 11/11/2011